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Abstract 
According to the American Cancer Society, one in four males and one in five females have a 
100% lifetime risk of dying from cancer. Cancer is a major burden on modern society, from stealing away 
precious years of health to putting stress on an already over burdened health care system. While some 
drugs might work better on general types of cancer, it is plausible to create cures for cancers based on 
specific mutations found within key regulatory proteins. Two complexes that are relevant to cancer 
biology, and are prime targets for drug modification, include a p53/DNA complex and a BARD1/BRCA1 
protein-protein dimer. Both complexes are commonly mutated in human cancers and many of those 
mutations inhibit formation of signaling complexes required for keeping cancerous growth in check.  
Using libraries of small, cyclic, genetically encoded molecules, made by the SICLOPPS method, it is 
possible to seek scaffolds for future cancer drugs. Before being able to screen with confidence, however, 
it is first necessary to study SICLOPPS molecule interactions on the functional screens used to monitor 
p53/DNA and BRCA1/BARD protein complex association and formation in order to learn how to 
optimize the screening process. In conclusion, insight was gained into how to use novel functional assays 
with SICLOPPS derived libraries and in the future large numbers of SICLOPPS molecules will be 
screened against important cancer associated complexes in order to rescue complex formation. 
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Chapter 1 - Introduction 
 
Mutations that inhibit formation of important cancer-check point protein complexes 
  
Protein interactions govern much of the biology that supports life. Proteins perform many 
basic functions including acting as signal transducers that moderate and support the metabolism 
of functioning organisms. However, when these protein interactions fail, a link is broken that can 
often lead to organismal catastrophe. The interactions of BRCA1, and its protein partner, 
BARD1, along with p53 and its ligand DNA, hold important functions within our cells that are 
absolutely necessary. When these complexes can no longer form, usually through mutation that 
causes perturbations within the proteins, dire consequences are the result.  
 The advances in protein chemistry yields hope for a solution to these problems. We 
propose a method of finding molecules that act as protein chaperones, helping to restore order to 
cellular function when mutations occur. Through a peptide library, made by the SICLOPPS 
method, we hope to discover drug scaffolds that could help in the fight against cancer. 
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A. P53 
 
i. The p53 protein significance in cancer development 
  
The study of the p53 protein has had a large impact on cancer biology since its discovery 
in 1979. The protein itself was discovered independently by two different groups when it was 
found that p53 complexes with the SV40 large T-antigen.1,2 Since it was discovered and 
implicated as a component in human cancer development thirty years ago, the gravity of the role 
of p53 has emerged in great detail. The knowledge base has evolved greatly over those thirty 
years, as it was first thought p53 acted as an oncogene in tumor formation, but since the mid 
1990’s it has been clarified that wild-type p53 acts as a tumor suppressor in vivo.3 In fact, p53 is 
inactivated in at least fifty percent of all human cancers.4 Besides being found in human cancers, 
tumors that contain p53 missense mutations are associated with poor prognosis and long-term 
survivability. This is largely due to resistance to chemotherapy that p53-mutation positive cells 
commonly display. It is hypothesized that chemotherapeutic drugs induce apoptosis in cancerous 
cells by channeling p53 apoptotic pathways, which cannot be activated in cells with existing p53 
mutations that result in functional loss.5 Mutations that inactivate p53 occur late in 
tumorogenesis, usually occurring after many other genomic instabilities and other allelic losses 
arise.6 It has been indicated that p53 inactivation is a rate limiting step for cancer growth in part 
to the late loss of function observed in tumorogenesis. Multiple groups have implicated that p53 
reactivation in cancer cells leads to cancer suppression in vivo.7,8 A well-known familial cancer 
syndrome called Li-Fraumeni Syndrome involved passing on germ line mutations of p53 
between family members. Families that carry Li-Fraumeni Syndrome show remarkably increased 
occurrences of diverse types of tumors at early ages.9 Similarly, mice homozygous for the p53 
null allele have been shown to develop cancer by six months of age while very small numbers of 
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homozygous and wild-type mice develop any type of cancer in the same time period.10 The Li-
Fraumeni Syndrome germlines and the p53 deficient mice points to the overall importance of 
p53 as a tumor suppressor in vivo. Small scale gene therapy trials have exploited this and has 
shown promising results using retrovirus-mediated p53 gene transfer into lung cancer tumors 
during clinical trials.11 However, rescuing p53 function via gene therapy is likely years away 
from being implemented as a panacea for cancer due to complications in the immune system 
response to vectors of wild-type p53 gene transfer and other limiting factors.12 This does show 
that restoring the function of p53 can lead to tumor suppression.    
ii. The role of p53 in vivo 
 
Activation of p53-dependent pathways depend on different kinds of cellular stress 
occurring in a cell. The first type of cellular stress shown to activate p53 was DNA damage. 
Kuerbitz  et al. gamma-irradiated to cause DNA damage in cell lines that didn’t contain 
endogenous p53 while also irradiating the same cell lines that had been transfected with wild 
type p53.13 This resulted in cell growth being stopped in the G1 phase in the cells containing the 
wild-type allele while the null allele cells did not stop replication. This indicated the important 
role of p53 to DNA damage. Additional cellular stresses have been shown to activate p53 cell 
senescence pathways, including oncogene activation, ribosomal stress, loss of cell to cell 
contacts, and hypoxia.14 Many different pathways of activation through post-translational 
modification have been suggested for p53. These include phosphorylation by stress-response 
kinases such as ATM, ATR, Chk1, and CHk2; Acetlyation by the p300/CBP complex, and 
stabilization through interaction of various other proteins including BRCA1, E2F1, and pRB.15 
Unstressed, normal cellular environments have very low concentrations of p53, due to a 
short half-life that is tightly controlled by the MDM2 protein. MDM2 acts directly on p53 as an 
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E3 ubiquitin ligase.16 MDM2 actively appends ubiquitin to p53 which targets it for destruction 
by proteolysis in the cell. MDM2 also indirectly controls p53 transduction via a negative 
autoregulatory feedback loop.17 
The main function of active p53 is as a cell cycle regulator. One of the first experiments 
to suggest p53’s activity as a cell cycle regulator was performed using colorectal cell lines, 
which lacked the p53 gene or contain missense mutations in p53, which showed a five to ten-fold 
decrease in proliferation in comparison to the same cell line that had not been transfected.18 This 
seminal experiment gave some of the first results indicating that p53 plays a major role in cell 
cycle regulation. p53 has also been noted to play important roles in cellular apoptosis.19 The 
activation of p53 allows it to carry out its main function as a transducer of important genes that 
encode important cell cycle regulators. Some of the important genes that p53 regulates includes 
the pro-apoptotic Bax genes, GADD45 genes which play a part in Cyclin B inhibition, and many 
others, including genes not yet characterized.20 To activate many of these pathways, p53 has been 
found to bind a consensus binding site characterized by Baker et al.18  The binding site is 
composed of two distinct copies, where each copy is called a half-site, of the 10 base pair motif 
of 5’-RRRC(A/T)(T/A)GYYY-3’ with 0 to 13 base pairs between the copies, where R is a purine 
and Y is a pyrimidine. The symmetry of the sequence has been shown to allow four monomers of 
p53, meaning that p53 binds as a tetramer to the consensus binding sequence. In fact, it has been 
shown by Weinberg et al. that p53 binding to the consensus binding site is highly cooperative 
and that a fully stable DNA/p53 complex requires the full length DNA binding site along with 
four monomers of p53.21 It  has also shown that common cancer mutations can cause a lack of 
tetrameric complex formation within the consensus DNA binding site.22 To understand why 
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many of these cancer mutations prevent complex formation, an understanding of the molecular 
structure of p53 is required. 
iii. The Structure of p53 
Figure 1. A schematic of the p53/DNA 
complex. The axis of the DNA molecule is 
perpendicular to the plane of the page.25 
 Human p53 is a 393 amino acid protein 
that has been historically divided into five 
different domains, albeit some functional 
properties overlap between these domains. The 
N-terminus of p53 is a very structurally plastic 
region that has not been found to have a 
tertiary structure.23 Within the N-terminus of 
p53 exists two of the five functional domains 
found within p53, with the first 64 amino acids being the transactivation region and the following 
65 to 92 amino acids the proline rich domain. Both regions play a role in the transcription of p53 
regulated genes.24 Residues 93-292 compose the DNA-binding region, the region that 
specifically targets the consensus binding site.25 Amino acids 324 to 361 makeup the 
tetramerizaion domain of p53, which is important for formation of the homotetramer/DNA 
complex.26 The fifth region, the regulatory domain, is composed of amino acids 362-392. It is a 
key domain that is often post-translationally modified for activation. Similarly to the N-terminus 
region, the regulatory domain is unstructured under physiological conditions and gains a 
secondary structure after binding to other proteins.27 A concise review of the domains has been 
written by Viadiu.28 
 The domain we focused on is the DNA binding core. According to the IARC TP53 
database, more than 80% of p53 mutations are found within this region.29 Studies using 
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proteolytic digestion have shown that the core domain is independently folded from the other 
regions of p53 and also that p53 contains a Zn2+ atom.30 The crystal structure of the DNA 
binding domain complexed with DNA, residues 93-292, was first done by Cho et al.25 The core 
itself consists of two antiparallel β sheets, with one sheet containing four strands and the other 
containing five. The two sheets pack side-by-side, forming a β sandwich Greek Key super 
secondary structure that is a very compact, hydrophobic core. At the site of DNA contact three 
loops and an α helix are important for DNA/p53 complex formation. The L1 loop (residues 112-
124) and the H2 α helix (residues 278-286) bonds with the pyrimidine bases in the consensus 
sequence in the wider major groove of DNA. The L3 loop (residues 236-251) forms important 
bonds with the more narrow minor grove of DNA within the adenine and thymine rich region of 
the consensus sequence. The L2 loop (residues 163-195) does not directly contact DNA but does 
have an important role in interacting with the L3 loop. The Zn2+ atom is ligated to three cystienes 
and a histidine, typical of many zinc-finger proteins, and has been shown to be very important in 
holding the tertiary structure, specifically the L3 loop, into this aforementioned structure by 
experiments done with chelating agents and a zinc-free p53 binding core crystal structure.31,32 
iv. Stability and structural studies of wild-type and mutant p53/DNA complexes 
  
Many of the experiments performed thus far attempting to quantify the stability of 
common core domain mutants in the literature use only the core domain, commonly residues 94-
292, instead of the entire 393 residues that typify the wild-type protein. It has been demonstrated 
by Ang et al. that four common destabilizing mutants cause identical destabilization as 
determined by the proteins apparent melting temperatures.22 This indicates two key proofs of 
principle: 1. The core domain can be used for stability studies of p53 mutants for function rescue 
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studies and 2. The core domain is pivotal in maintaining the overall stability of the full-length 
protein.  
 As mentioned previously, many of the mutations found in p53 are located within 
the core domain. The six most common mutated residues (Arg175, Gly245, Arg248, Arg249, 
Arg273, and Arg282) are indeed located within the DNA-binding surface of the core domain.29 
Most core domain p53 mutations fit into two distinct categories, dependent on their location. 
DNA/p53 contact mutants, such as R248Q and R273H, change a residue into one that can no 
longer bond with DNA.33 Structural mutations make up the second class, which are exemplified 
by R175H, G245S, R249S, and R282W. This second class of mutations is likely to alter the 
structure of the p53 core domain in a way that effects the abilities of other key residues to make 
contact with DNA. 
The wild-type p53 binding domain has been demonstrated to be very sensitive to changes 
in temperature at 37 °C. During urea-induced denaturation wild-type p53 forms an aggregate at 
37 °C, a calculated Tm of only 42 °C, and at 25 °C the free energy of unfolding is only 6.0 
kcal•mol-1.34 This implies that even slight changes in p53 stability would likely result in 
universal unfolding and loss of function.  Indeed, it has been shown that slight changes do cause 
global denaturation of common cancer mutation containing p53 core domains, as a decrease of 
free energy between 0.5 kcal•mol-1 and 2.0 kcal•mol-1 will strongly distort the folded state and a 
change of 3.0 kcal•mol-1 is likely to cause global denaturation and total functional loss.35  
 A stabilized p53 variant designed by semirational methods has been created by Nikolova 
et al.36 They selected 22 homologous proteins and identified candidates for point mutation 
substitutions along with incorporating another mutation, N239Y, that had been reported to be a 
second site suppressor mutation for the mutation G245S. After utilizing four mutations that 
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increased thermostability, found by consensus analysis, one stabilized p53 protein was created 
with the mutations M133L, V203A, N239Y, and N268D. The Tm of the quadruple mutant was 
calculated to be 47.2 °C, a significant improvement over the wild-type p53 Tm of 42 °C. The 
crystal structure of the quadruple stabilized mutant has shown to create additional hydrogen 
bonds with the consensus DNA binding sequence, thus stabilizing it.37 The stabilized mutant has 
been implicated in use for gene therapy but also suggests that p53 can be stabilized by creating 
additional linkages within the DNA/p53 complex. The crystal structures of many destabilized 
mutants have been solved using the quadruple stabilized core domain protein.33 
 From the change of free energy and quadruple stabilized mutant experiments a method of 
functional rescue for p53 mutant destabilizing mutants can be derived. If more linkages can be 
created between the p53 binding domain and the DNA consensus sequence, then it is plausible 
that the p53 mutant molecule could be stabilized, allowing for transcription of important p53 
controlled regulatory genes. While this has been done by creating second site suppressor 
mutations to create the quad mutant, it is also plausible that this could be done by the addition of 
a small molecule that is either bound to p53 and assisted in molecule binding or by binding both 
p53 and the DNA sequence.36 
v. The negative p53/consensus binding domain screen 
To date, have been limited developed screens that can detect if p53 is stable enough to 
form a p53/DNA complex. A screen of this type would be greatly helpful in                          
identifying molecules that direct help make p53 a better co-partner of the p53/DNA consensus 
binding domain dimer. Brinda Ramasubramanian, a graduate student in Magliery lab, has 
constructed a plasmid based system of p53/consensus binding domain complex formation. Using 
a pGFPUV vector (figure 2), a p53 consensus binding 
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domain was cloned in between a HindIII 
and NheI  restriction site, effectively replacing the 
lactose operator in the parental plasmid.38 The 
idea behind the screening vector is that p53 
variants that are stable will bind to the consensus 
binding domain tightly and GFP production will 
be inhibited. P53 variants that are destabilized 
will not bind to the domain tightly and fluorescence will occur. 
Figure 2. The pGFPuv plasmid with the 
restriction sites used for cloning highlighted. 
 As a proof of principle, the stabilized quadruple mutant p53 variant, described here 
previously, has been shown to inhibit fluorescence production in this system while wild type p53 
does not. The reason wild type p53 likely does not pass the screen is that p53 has been shown to 
be destabilized even at body temperature. This means that the wild type is too unstable to bind 
the consensus domain. 
[9] 
 
B. BRCA1 
 
i. The BRCA1 protein significance in cancer development 
 
 Breast Cancer Susceptibility Protein 1 (BRCA1) was linked to cancer development by a 
genetic analysis of breast cancer in certain families that located common mutations in breast 
tumors to the 17q21 chromosome in 1990.39 Statistical analysis by Ford et. al, showed that 
familial breast cancer predisposition is correlated to mutations within BRCA1.  They have 
calculated a 100% percent lifetime risk of either ovarian or breast cancer in those who carry 
BRCA1 germline mutations.40 Current chemotherapeutics used against breast cancer have mixed 
results in use with patients carrying BRCA1 mutations.41 
Tumor cell lines that are BRCA1 deficient display a higher death rates after exposure to 
Gamma-rays than cell lines that have active wild-type BRCA1, indicating an inability to cope 
with stress that causes DNA damage. 42 A conditional mutant mouse model of BRCA1 develops 
mammary tumors that show very similar chromosomal instabilities to human breast cancer, 
indicating a major role for BRCA1 in breast cancer.43 It has been postulated that BRCA1 
deficient cell lines cannot begin cancer formation unless oncogenic mutations occur in other 
important tumor growth inhibiting proteins. The loss of BRCA1 in mouse embryos leads to 
lethality in the presence of mice positive for p53, while the haploid loss of p53 in the same 
model leads to rescue from embryonic lethality. However, mouse embryos deficient in BRCA1 
and haploid deficient in p53 develop mammary tumors at an abnormally high rate and eventually 
lose the remaining wild-type allele of p53.44,45 
An important binding partner of BRCA1, BRCA1-associated ring domain protein 
(BARD1), has been implicated in tumor suppression upon complex formation with BRCA1. The 
loss of BARD1 results in embryonic lethality and genomic instability.46 Conditional mutants of 
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BARD1 have similar levels of chromosomal instability as BRCA1 conditional mutants.47 This 
implies both proteins are needed for BRCA1 to act as a tumor suppressor in vivo.  
ii. The role of BRCA1 in vivo 
  
BRCA1 is implicated in many of the responses to DNA damage. Most notably, BRCA1 
has been shown to play a major role in chromosomal stability.48 BRCA1 associates with Rad50, 
the homolog of the bacterial RecA protein, in the endogenous response to DNA double strand 
breaks.49 BRCA1 has been associated with many transcription factors, most importantly estrogen 
receptor-α, STAT1, and p53.50 BRCA1 is involved in DNA decatenation in association with 
topoisomerase IIα during the S phase of mitosis.51 
Another function BRCA1 plays in response to cellular stress is the ligase function it 
performs by appending ubiquitin molecules onto a varying array of substrates., including 
autoubiquitination of the complex formed BRCA1/BARD1 association.52 Importantly, this 
ubiqutination function has been shown to be important in the response to DNA damage.53 
BRCA1 has been implicated in the ubiqutination of many important proteins, including 
FANCD2 , a protein associated with specific types of cancer, and RNA polymerase II, as a 
method of degrading stalled replication forks, allowing access for repair machinery.54,55 While 
BRCA1 can still act as a ubiquitin ligase as a monomer, the ubiquitin ligase activity is 
dramatically increased once BRCA1 complexes with BARD1.56 Also, the stability of BRCA1 is 
increased upon association with BARD1.57 
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Figure 3. RING domain produced via NMR from 
the Equine Herpes Virus, 1-Gene 63.62 
iii. The Structure of BRCA1and BARD1  
  
BRCA1 is composed of 1,863 amino acids.58 Currently, no crystal structures have been 
reported of the full-length protein. However, two 
important segments of BRCA1 have been thoroughly 
characterized to date. The C-terminal region contains 
two 90-100 amino acids motif repeats deemed the 
BRCA1 C-Terminal repeats (BRCT), amino acids 
1646-1863.59 The other region, which we focused on, is 
the RING finger domain and the flanking sequences 
contained within amino acids 1-109 of the N-Terminal 
of BRCA1. This region was found by Meza et al. to be 
the minimal sequence possible for complex formation of BRCA1 and BARD1.60 Residues 23-76 
compose the Really Interesting New Gene (RING) finger domain while the remaining sequences 
are necessary for formation of the functional domain. Many important protein-protein 
interactions are mediated through RING finger motifs.61 These motifs contain two bound Zn2+ 
molecules with each atom ligated tetrahedrally, by either four cysteines or three cysteines and a 
histidine, in a unique cross brace system. A central α-helix links the two Zn2+ binding sites.  The 
cross brace system based on zinc ligands is important for stabilization of the RING motif.62 
Residues 8-22 and 81-96 of BRCA1 are composed of antiparallel α-helices that flank and are 
largely held into correct conformation needed for BARD1 association by the RING domain.63 
[12] 
 
Figure 4. BRCA1/BARD1 protein complex.63 
BARD1 is composed of 777 amino acids and 
first suggested to be an important binding partner of 
BRCA1 after being found to interact in a two-hybrid 
yeast screen.64 BARD1 was found to need only 
residues 26-131 in order to form the BRCA1/BARD1 
complex.60 BARD1 contains a RING motif within that 
segment, residues 49-100. The RING residues in 
BRCA1 and BARD1 are almost identical albeit the 
RING motif in BARD1 contains five fewer amin
acids, which are found as a central helix within the third and fourth pairs of Zn2+ ligands in 
BRCA1. 63 Also, both the amino terminus and carboxy terminus of the RING motif in BARD1
residues 36-48 and 101
o 
, 
-116, are flanked by antiparallel α-helices.  
 
iv. Mutational Studies of the BRCA1/BARD1 protein complex 
  
Twenty percent of mutations considered clinically relevant are located within the first 
100 amino acids of BRCA1, a region containing the RING domain. (Breast Cancer Information 
Core Website)  Two general classes of mutations are commonly seen in the BRCA RING 
domain and flanking antiparallel α-helices. The first class consists of mutations that affect the 
Zn2+ residues within the RING-finger motif. The known cancer mutation C61G, which alters a 
conserved site II Zn2+ binding ligand in BRCA1, results in proteolytic susceptibility indicating 
global unfolding when compared to the proteolytic degradation resistance of the wild-type 
BRCA1 RING motif.65 While some mutations within the RING domain totally inhibit the 
formation of the BRCA1/BARD1 complex others commonly seen in this region do not, yet the 
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latter mutations still inhibit the E3 ubiquitin ligase function of the complex.66,67 This could either 
be from the result of a less stable BRCA1/BARD1 complex or the rearrangement of the cleft 
needed for E3 ligase function.68 
The second class of mutations involves alterations within the dimerization interface of the 
antiparallel α-helices. Several common mutations seen in patients line this region.63 Mutational 
studies done on BARD1 have shown that changing the strongly hyrdrophobic amino acids that 
line the dimerization interface to hydrophilic amino acids will inhibit formation of the complex.69 
There are no known mutations seen in patients within the RING motif and antiparallel α-
helices or BARD1.70 It is unknown why mutations similar to those found in BRCA1 are not 
found in BARD1. However, the fact that only the RING motif of BRCA1 plays a role in E3 
ligase activity probably plays a role in this strange finding.68 
 
v. The Split GFP-screen 
  
 In order to directly assess the BRCA1/BARD1 dimer, some form of functional assay is 
needed to report if the complex has formed. Screens that detect protein-protein interactions have 
been developed and utilized with varying success for many different protein-protein interactions. 
Yeast two-hybrid systems, fluorescence resonance energy transfer (FRET), tandem affinity 
purification (TAP) , split protein complementation assays, and protein microarrays are 
commonly used methods of detecting protein-protein interactions in vivo and in vitro.71,72  
Among those, split protein complementation has risen to become a very powerful tool in 
discovering and detecting protein-protein interactions.  
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 The paradigm for a split complementation based on green fluorescent protein (GFP) was  
first proposed by Ghosh et al.73 The actual assay 
was developed and tested by Magliery et al.74 
The split-GFP screen is fluorescent when each 
half of the split GFP protein is bound to two 
copartners of an active protein-protein complex. 
Importantly, GFP does not fluoresce unless a 
stable complex is formed.67 
Figure 5. The Split-GFP reassembly protein. 
The green segment is the N-terminal half and 
the red segment is the C-terminal half.67 
 The assay has been used to identify mutations 
that inhibit formation of BRCA1/BARD1 complexes. 
Pairing the split-GFP assay with libraries of drug-like molecules is a potential way to find drug 
leads that ameliorate the binding problems caused by BRCA1 mutations found in common 
cancers can present.  
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C. Small Molecules Used As Chemical Chaperones 
i. Previous Work Utilizing Small Molecules to Rescue Misfolding Mutations 
  
A great body of evidence has mounted suggesting many protein-protein interactions are 
governed not by large numbers of weak interactions over a large area but a small number of 
important residues in small patches.75 This idea can be applied to the use of small molecules as a 
method of rescuing protein-protein binding problems. An ideal location of binding was called a 
“hot spot” by Clackson and Wells. Hot spots have roughly the size of small organic molecules, 
opening the possibility of a very small molecule that could strongly bind to these hot spots in 
order help mediate protein-protein interactions. This discovery has led to small molecules that 
function in this way: Nutlin, an inhibitor of MDM2 and an inhibitor of Bcl-2 family proteins.76,77 
Figure 6. PhiKan083 within the cleft created by the 
Y220C mutation.81 
 Mutations found within the core domain of p53 are considered drugable by small 
molecules because destabilized mutants have melting temperatures below body temperature, 
giving these unstable proteins incredibly short half-lives.78 If a molecule could selectively bind to 
the wild-type conformation of p53 then the half-life of p53 in vivo would greatly increase. CDB3 
was the first molecule found to stabilize misfolded 
p53.79 Following the discovery of CDB3, PRIMA-1, a 
different molecule, was found to also stabilize p53 
although it is not entirely clear how PRIMA-1 does 
this.80 However, the best example of a small molecule 
utilizing a Clackson and Well “hot spot” is 
exemplified by PhiKan083.81 PhiKan083, which was 
found via In Silico screening, fits within a cleft in the 
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Y220C p53 core domain mutant and has been shown to stabilize that variant of p53.  In fact, the 
cavities that exist on the surface of Y220C have recently been characterized.82 It is very evident 
that small molecules have great potential as modulators of protein function. 
ii. SICLOPPS Libraries as a Method of Complex Formation Rescue 
In general, peptides and small proteins have been shown to be good tools for modulating 
enzymes and other proteins.83 However, the use of peptides as drugs is limited due to proteolysis 
caused by many of the proteolytic enzymes that exist in human blood and organs.84 Also, linear 
peptides can have low specificities to binding sites due to the need to overcome large 
conformational entropy loss in order to adopt a single major conformation.85 Cyclization of 
peptides has been shown to be a good method of circumventing both of these pitfalls. 
Introducing a constraint to peptides reduces the number of conformations possible, thus lowering 
the entropic loss needed to be overcome for binding to occur. This method has been successfully 
employed in developing a cyclic peptide that binds with much greater affinity to Streptavidin 
compared to the linearized peptide.86 Also, this makes it less likely the peptide will take on a 
conformation that is able to fit within the cleavage sites of proteases.  
 Libraries made by the Split Intein-mediated Circular Ligation of Peptides and Proteins 
(SICLOPPS) method are good candidates for modulators of protein function.87 Because the 
libraries are genetically encoded and produced in vivo the molecules do not need to cross the 
cellular membrane, a confounding factor that often hinders in vivo screening of synthetic 
molecules. Also, library members that are toxic will kill the cells that contain it, eliminating them 
from further being screened as possible drug scaffolds. However, the library is similar to 
synthetically derived libraries because of the wide variance in amino acids used at each position. 
A library containing five variable residues has over 3.2 x 106 different library members, owing to 
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a possible 20 amino acids at each position. The library size makes the library more like a 
synthetic library while still being produced using cellular machinery. This also opens up the 
possibility for functional screening for molecules based on phenotypic selection within the cells. 
Because of the ease of screening many bacteria at one time, this opens an advantageous way of 
discovering possible peptide modulators of protein function. 
Figure 7. Circular Ligation Mechanism.87 
This protein trans-splicing mechanism is derived from the dnaE gene of Synechocystis 
species PCC6803.88 The dnaE gene transcript is made of two distinct segments. After trans-
splicing the extein segments form one long protein fragment while the intein segments are 
spliced out. In the methodology developed by 
Benkovic, The C-intein segment is placed at 
the N-terminus of the sequence to be cyclized 
and the N-intein is placed at the C-terminus of 
the sequence. Once the gene is translated the 
N-intein and C-intein segments fold and form 
the active intein complex. Once this occurs a 
sulfhydryl side chain, which lies within the C-
terminal intein as decribed by Scott et al., 
undergoes nucleophilic attack of the carbonyl 
carbon of the amino acid directly beside the 
sequence to be cyclized. This forms a thioester lariat intermediate. Following this, an asparagine 
residue cyclizes to form a lactone.  The intein then self-liberates, via an isomerization reaction, 
causing the sequence to form a lactam ring that is backbone cyclized from the N-terminus to the 
C-terminus of the sequence. 87,89 
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There are limitations on what residues can be placed at the positions within the sequence 
to be cyclized beside the N-intein and C-intein segments.90 It appears the position directly beside 
the C-Intein, in the N-terminus of the sequence, can tolerate only a limited number of residues. 
Two different groups have shown that a cysteine must be placed immediately beside the 
sequence to be cyclized.90,91 The position on the C-terminus beside the N-intein segment can 
seemingly tolerate any residue, as this residue does not actively participate in the reaction 
mechanism. From the same studies, it appears there is limited selection for specific residues at 
other positions, meaning that library members theoretically should be diverse in the residues 
utilized.  
SICLOPPS libraries have been used to discover possible drug scaffolds with success. 
SICLOPPS libraries have been used to find molecules that inhibit Dam Methyltransferase, 
molecules that decrease α-synnuclein toxicity in Parkinson’s disease yeast models, and inhibitors 
of ribonucleotide reductase.91,92,93 Given these past success, SICLOPPS libraries hold great 
promise for modulating other protein-ligand interactions which could lead to new drug scaffolds. 
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Chapter 2 - Methods 
 
A. Materials 
Most chemicals were purchased from Sigma, Aldrich, Fisher, and American 
Bioanalytical. Ampicillin, kanamycin, and Isopropyl β-D-1-thiogalactopyranoside (IPTG) were 
bought from Research Products International and American Bioanalytical. 1000X stock solutions 
of Ampicillin, Kanamycin, and IPTG were made as follows; 100 mg mL-1 ampicillin, 35 mg mL-
1 kanamycin, and 100 mM IPTG. The concentration of IPTG, however, depended on the final 
concentration needed as has been specified when used differently. L-Arabinose was purchased 
from Benton Dickson and made in 19.6%(w/v) solutions. Ampicillin, kanamycin, IPTG, and 
arabinose was sterile filtered using 0.2 µm syringe filters (Milipore). Nucleotide Triphosphates 
were purchased from American Bioanalytical individually at 100 mM concentrations and mixed 
equimolar to 10mM stock dNTP solutions. Restriction enzymes, Ligases, and electrophoretic 
molecular weight standards were purchased from New England Biolabs. Herculase polymerase 
and associated buffers were purchased from Stratagene. Oligonucleotides were purchased from 
Sigma-Genosys and resuspended in purified water to 100 µM solutions. The E. coli DH10B 
cloning strain and the E. coli BL21(DE3) expression strain were both gifted from the Lynne 
Regan lab. The pET28b-Npulc/In-SICLOPPS vector was a gift from the Stephen J. Benkovic 
Lab. The pGFPUV vector was gifted from Peter Schultz. Water used for molecular biology, 
specifically for making stock solutions of various chemicals, digests, ligation, and in other 
protocols, was purified using a Barnstead NANOpure Diamond system to 18MΩ·cm. Plasmid 
isolation was done using EconoSpin™ DNA spin columns from Epochlabs, using a miniprep 
vacuum manifold from Qiagen and buffers made within the lab according to recipes provided by 
Epochlabs.  
[20] 
 
PCR was performed using a C1000™ Thermal cycler (BioRad) with a heated lid on. 
Concentration of DNA was done using a Savant SC110 speed-vac with low or medium heat. 
Electrophoresis was performed in a 10 cm horizontal gel apparatus using 1% agarose gels. A 
BioRad PowerPac Basic was used as a power supply for all electrophoresis done. Electroporation 
was done using a BioRad Micropulser in 0.2 cm electroporation cuvettes purchased from USA 
Scientific. Cell culture was typically carried out in 50 mL Falcon tubes made by Becton Dickson 
or 14 mL polystyrene Becton Dickson Falcon tubes (for recovery of cells) or 14 mL 
polypropylene Becton Dickson Falcon tubes (for general growth). Centrifugation was done in an 
Eppendorf 5415 D centrifuge (for small volumes typically <3 mL), an Eppendorf 5810 R (for 5-
50 mL volumes), or a Sorvall RC-6 centrifuge (for high speed and large volumes >50 mL). Cell 
density measurements were determined by Agilent 8453 UV-visible spectrophotometer. Pictures 
of plates were done using a Canon Powershot A550 camera. Fluorescence was determined by 
visual inspection of plates on a High Performance UV Transilluminator (UVP) and recorded 
using Kodak software.  
B. General Protocols 
 All enzymatic reactions were carried out using conditions suggested by the reagent 
supplier, with deviations from this if needed. The standard PCR reaction was a 25 µL or 50 µL 
reaction volume using Herculase II (Stratagene) in 5X Herc II buffer (provided with Herculase), 
4 uM primers, 250 µM dNTPS, 0.5 unit or Herculase, and 0.02 mM uL-1 of template DNA. 
Typically, each PCR was done using thirty cycles of denaturation, annealing, and extension. A 
typical first denaturation was for two minutes at 95 °C with subsequent denaturation being thirty 
seconds also at 95 °C. Annealing was done for thirty seconds with a temperature dependent on 
primer specific annealing temperatures. For most PCR reactions the annealing temperature was 
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60 °C or calculated using five to ten degrees below the lowest annealing temperatures between 
the two primers. Annealing temperatures were derived from the program OLIGOTECH. 
Extensions was done at 72 °C and for a time determined by the length of the amplified region 
desired, generally calculated by one minutes per 1 kilobase of product. A final extension 
temperature was done at 72 °C for 5-8 times longer than the extensions done in the previous 
cycles. All PCR products were analyzed using agarose gel electrophoresis to determine if the 
desired product was achieved. The restriction enzyme DpnI, which only cuts methylated 
template DNA, was added at 0.2 units mL-1 of PCR reaction after all SICLOPPS library insert 
amplifications. PCR products were purified using the QiaQuick PCR purification protocol 
provided by Qiagen, with the only exception being a different buffer instead of PB (I used PB1 
as described by Epochlabs). 
 Restriction digests were done as according to the protocols given by New England 
Biolabs. Ligations were typically done as according to New England Biolabs protocols, with the 
amount of DNA depending on if a single clone or complete library was desired. Phenol-
Chloroform-isoamyl alcohol/Chloroform-isoamyl alcohol followed by ethanol precipitation 
and/or agarose gel purification with a QG cleanup (as described by Qiagen) was done in order to 
clean up DNA fragments produced after restriction digest. 
 Fresh electrocompotent cells (DH10B or BL21(DE3)) were prepared by the author after 
successful ligations of all libraries to ensure maximum transformation efficiency and maximal 
library coverage. Electrocompotent cells were prepared in 0.5 L or 1.0 L volumes of culture in 
2YT liquid media. Seed cultures (1/40 dilutions of the preparation amount) were inoculated from 
single colonies of the strain desired and grown to saturation (12 to 14 hours) at 37 °C. The seed 
was then used to inoculate the preparation amount and the preparation was grown at 37 °C to an 
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absorbance of 0.5 O.D. at 600 nm and then vigorously shaken in ice water for five minutes. The 
culture was always kept in ice throughout the following process. The preparation was then 
centrifuged in the Sorvall centrifuge at 7,000 RPM for five minutes, the supernatant was pulled 
off, and the pellet was resuspended in 4 mL of ice cold autoclaved 10% glycerol (v/v). A second 
identical centrifugation, resuspension and centrifugation was preformed. After this the 
supernatant was pulled off and the pellet was resuspended in small amounts of 10% glycerol 
(v/v) and aliquoted in 100 µL amounts and then flash frozen in dry ice. All electrocompotent 
cells were stored at -80 °C for future use. All electrocompotent cells quality controlled by 
electroporating an aliquot of the preparation, resuspending the electroporated cells in 1 mL of 
2YT, recovery with vigorous shaking at 37 °C for one hour, and then plating 200 µL on separate 
Luria-Bertani(LB)/ampicillin and LB/kanamycin plates. If no cells grew after 16 hours of 
incubation at 37°C then those cells were deemed contamination free.  
 Electroporation was done by mixing 1 µL (103 dilution for single variant plasmids or 
undiluted for libraries) miniprepped, circular DNA in 40 µL electrocompotent cells (for single 
variants) or 100 µL electrocompotent cells (for libraries, in order to ensure maximal diversity 
retention). Immediately after electroporation, the cells were resuspended in 1 mL of 2YT and 
recovered at 37 °C for one hour. The culture was then spread on LB plates with the desired 
antibiotic resistance. 
 The transformation efficiency of all libraries after transformation into electrocompotent 
cells was quantified by pouring all quenched, electroporated cells into 1 L of 2YT, recovery for 
one hour, and then plating 103, 104, and 105 dilutions on LB plates with the required antibiotic 
resistance. After 12 hours of incubation at 37 °C, the numbers of colonies on the plates were 
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counted and a back calculation was performed in order to make sure all libraries were 
represented ten fold over the size of the given library.  
 All cells desired to be saved for long periods of time were glycerol stocked by adding 0.5 
mL of 50% glycerol (v/v) to 1 mL of saturated culture in 2YT grown with the associated 
antibiotic. The mixture was then flash frozen in dry ice and then kept in -80 °C for long term 
storage. 
 DNA sequencing was performed by Genewiz. According to their protocol, each 
sequencing reaction contained the following components; 6 µL of plasmid miniprep, 4 µL of 
2mM primer, and 2 µL of water. For sequences greater than 800 base pairs, two primers were 
used, a forward and a reverse to ensure coverage. All alignments were done using ClustalX2. 
 All plates made by the authors hands, or fellow lab members, and were allowed to dry for 
24 hours at room temperature before being used. All screening plates that contained arabinose 
and/or IPTG were used within 36 hours of being made. 
C. P53 methods 
i. Cloning and glycerol stocking of the SICLOPPS Library 
  The SICLOPPS library was a given to 
us from Charles Scott, Thomas Jefferson 
Medical Center. The library was genetically 
encoded within a pET-28b vector (Novagene). 
The DnaE intein was cloned between a NcoI 
and XhoI site. The NcoI site was destroyed. T
variable region was cloned in between the split 
inteins using an AflII and MfeI site. The librar
Figure 8. pET28-SICLOPPS plasmid. 
he 
y, 
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encoded by the region between the AflII and MfeI sites, contains cysteine that is constant in 
every SICLOPPS molecule and four variable positions. All SICLOPPS molecules the
contain five amino acids by this design. According to this, the maximum number of unique 
SICLOPPS molecules is 160,000.  
oretically 
 We were given dehydrated plasmid which was resuspended in water and then 
electroporated into fresh DH10B produced as described above and glycerol stocked for future 
use. 
ii. Cloning of the SICLOPPS library into the pGFPUVbd1 vector 
 Primers were designed to append an AatII restriction site to the 5’ end of the SICLOPPS 
library and a SpeI site to the 3’ end of the library. The following primers were used to amplify 
the library using the Pet28-SICLOPPS vector as a template, using the PCR protocol described 
previously. 
 
Figure 9. pGFPuvbd1/SICOPPS cloning primers 
Primer Name Primer Sequence (5’ to 3’) 
SICLOPPS-SpeI AATAATAATACTAGTTAATCGCCGCGACAATTTGC 
SICLOPPS-AatII  ATTATTATTGACGTCTCAGTGGTGGTGGTGGTGGTG 
After PCR amplification, DpnI digest, and Qiagen PCR cleanup (all as previously 
described), the amplified fragment was double digested using AatII/SpeI and then purified using 
agarose gel extraction followed by a QC cleanup. 
At the same time, the pGFPuvbd1 vector, created by Brinda Ramasubramanian, a 
graduate student in Magliery lab, was double digested using restriction enzymes that are cut 
specifically at unique sites within the pGFPuvbd1 vector and also within sites appended to the 
ends of the SICLOPPS library insert fragment. The pGFPuvbd1 vector was double digested, with 
a phenol-chloroform-isoamyl alcohol/chloroform-isoamyl alcohol followed by ethanol 
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precipitation step in between each digest. The double digested pGFPuvbd1 vector was then 
agarose gel extracted followed by a QC clean-up.  
The cut and purified SICLOPPS insert fragment and the pGFPuvbd1 vector were then 
concentrated using the Savant SC110 speed vac. Two ligations were performed, a control 
pGFPuvbd1 background assessment ligation and a ligation of the pGFPuvbd1 vector and the 
SICLOPPS insert, hereon deemed the “combined” ligation. A 20 µl reaction volume was used 
for both ligations, with the following components; 2 µl of 1X T4 ligase buffer, 0.5 µl of T4 
ligation (~300 ng), and water to bring to the total reaction volume desired. Ligations were done 
at 16 °C for 24 hours. After ligation, both the control and the combined ligation were double 
digested with EagI and BsiWI restriction enzymes in order to linearize any background parental 
pGFPuvbd1 vector still present in the ligations. This preparation was electroporated into DH10B 
and 100 µL of those cells was plated to enumerate background contamination and transformation 
efficiency on LB/ampicillin plates. The CFU for both plates were analyzed in order to check 
background levels and transformation efficiency.  
iii. Purity Assessment of the pGFPuvbd1/SICLOPPS library 
 A saturated culture of the DH10B/pGFPuvbd1-SICLOPPS library was grown and 
miniprepped. The plasmid DNA was then double digested using the cloning sites (AatII/SpeI).  
Purity of individual SICLOPPS clones was assessed by plating 150 µL of saturated 
plasmid contained DH10B, diluted by a factor of 104, on LB/ampicillin plates and picking ten 
random variants. These variants were miniprepped and digested using the cloning sites 
(AatII/SpeI).  
Three of the ten individual clones were sequenced using the following primers (reverse 
and forward).  
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Figure 10. pGFPuvbd1/SICOPPS sequencing primers 
Primer Name Primer Sequence (5’ to 3’) 
p53-SICLOPPS Forward GAATTCCAACTGAGCGCC 
p53-SICLOPPS Reverse GAAAAATAAACAAATAGG 
  
iv. Optimization of the p53WT screen in BL21(DE3) 
 Brinda Ramasubramanian created the screen and optimized it for the DH10B strain. The 
screen needed to be optimized for usage of the BL21(DE3) expression strain. In order to 
optimize fluorescence of the p53 binding screen a positive control , the quadruple stabilized 
mutant p53, and a negative control, p53 wild type(WT), were separately co-transformed along 
with the pGFPuvbd1 plasmid into BL21(DE3).  
 Arabinose concentration was first optimized at different temperatures and times. Then 
IPTG concentration was optimized in the conditions deemed best for the Arabinose 
concentration. The following concentrations of arabinose and IPTG and also time and 
temperature variations were used to optimize conditions for screening: 
Arabinose: 0.01%, 0.0075%, 0.005%, 0.0025%, 0.001%, 0.00075%, 0.0005%, 0.00025% 
IPTG: 10 mM, 1 mM, 0.5 mM, 0.1 mM, 0.05 mM, 0.01 mM; Temperature: 30°C, 37°C; Time: 
12 hours, 18 hours, 36 hours, 48 hours. 
v. Assessment of SICLOPPS molecule affect on the p53 screen 
To access if SICLOPPS molecules had an effect on the p53 screen two experiments were 
set up: DH10B strain with the pGFPuvbd1-SICLOPPS plasmid on an LB/ampicillin plates and 
BL21(DE3) strain with the pGFPuvbd1-SICLOPPS plasmid grown on LB/ampicilin-0.1 mM 
IPTG. These were incubated for 16 hours at 37 °C.  
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 vi. Reversion of the SICLOPPS library with pGFPuvbd1 
 The method for cloning the reversion of the SICLOPPS library is identical to that used to 
originally clone the library into the pGFPuvbd1 plasmid. The only different is that the sites of the 
AatII and SpeI sites on the primers have been switched. 
 
Figure 11. pGFPuvbd1/SICOPPS reversion primers. 
Primer Name Primer Sequence (5’ to 3’) 
Bd1GFP-SCI-AaTII AATAATAATGACGTCTAATCGCCGCGACAATTTGC 
Bd1GFP-SCI-SpeI ATTATTATTACTAGTTCAGTGGTGGTGGTGGTGGTG 
  
vi. Selection and purification of SICLOPPS peptides 
 A saturated culture of 150 µL BL21/pGFPuvbd1-SICLOPPS , diluted by a factor of 103, 
was plated on an LB/ampicilin-0.1 mM IPTG and grown for 16 hours at 37 °C. Eighteen low or 
non-fluorescent CFU were picked, cultured, and glycerol stocked. Four of these were expressed 
for SICLOPPS molecules using the following protocol. A 1 mL seed of 2YT/ampicillin was 
grown to saturation at 37 °C for 12 hours. A 1/40 amount of final preparation (0.625 µL) of the 
seed was added to 25 mL of 2YT/ampicillin and grown to between 0.6-0.8 O.D. The cultures 
were then induced by adding 2.5 µL of 1 M IPTG to give a final concentration of 0.1 mM IPTG. 
The cultures were then moved to a 28 °C shaker for 24 hours. After that time, the cells were spun 
down at 3,200 RPM for 25 minutes at 4 °C. The supernatant was removed and the pellets were 
placed in -80 °C for storage. The pellets were thawed on ice. A 1/40 (0.625 µL) amount of 
preparation of lyses buffer ( 50 mM Tris-HCL, 300 mM NaCl, 10 mM imidazole, 10% (v/v) 
glycerol) (0.625 µL) was added to the pellets and the pellets were resuspended. 0.1 mL of 0.1 
mm glass beads (Biospec) were added and the mixture was vortexed for thirty seconds and then 
[28] 
 
chilled on ice for two minutes, repeating five total cycles of vortexing and cooling. The mixture 
was then spun down at 4 °C for 30 minutes at 13,200 RPM. The supernatant was pulled off and 
heated to 85 °C for 15 minutes. The solution was then spun 4 °C for 30 minutes at 13,200 RPM. 
The supernatant was pulled off and n-butanol extracted. Both the aqueous and butanol layers 
were saved. Both layers were dried using the spin-vac. 
viii. MALDI-TOF analysis of SICLOPPS variant lysates 
 The matrix was made by saturation of α-Cyano-4-hydroxycinnamic acid in 50% 
acetonitrile (v/v), 50% water, and 0.1% Trifluoroacetic acid. 2 µL of this matrix was added to 1 
µL of resuspended lysates (30 µL of water was added to the dried pellet and vortexed). The 
samples were analyzed using a Bruker MicroFlex mass spectrometer. 
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 D. BARD1/BRCA1 methods  
i. Stuffer fragment cloning into pET11A-BARD1 
Figure 12. A. pET11a-BARD1 with eventual clone in sites for the SICLOPPS library 
B. pGFPuvbd1 with stuffer fragment between EcoRI-HF and AatII site. Multiple background digest sites are shown in between 
the cloning sites. 
A lack of two unique restriction sites within the pop out of pET11a-BARD1, a plasmid 
designed by Mohosin Sarkar of the Magliery Lab, led to the need for cloning a “stuffer” 
fragment with the sites that would eventually be used for cloning the SICLOPPS library into 
pET11a-BARD1.  DH10B with a pET11a-BARD1 plasmid (ampicillin resistance) and, 
separately, DH10B with pGFPuvbd1 was grown 12 hours in 2YT/ampicillin at 37 °C, 
miniprepped, and digested with EcoRI-HF and AatII. Two 5 µL ligations, a background ligation 
with only pET11a-BARD1 vector and a combined ligation with both pET11a-BARD1 vector and 
pGFPuvbd1 insert, were performed with the following ingredients; 0.5 µL of 1X ligation buffer, 
0.2 µL of ligase, 3 µL of pET11A-BARD1 digest (50 ng), 1 µL of pGFPuvbd1 digest (combined 
ligation only, ~50 ng), and brought each ligation to 5 µL. Each ligation was done at 16 °C for 24 
hours. Each ligation was then transformed into DH10B and the 100 µL of recovery was plated on 
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LB/ampicillin. The combined ligation plate was observed under UV light (302 nm λ) and ten 
non-fluorescent colonies were selected. 
 The ten colonies were digested with the cloning restriction enzymes and run on an 
analytical gel. Three of the variants were sequenced. 
 
Figure 13. pET11a-BARD1 sequencing primers 
Primer Name Primer Sequence (5’ to 3’) 
SICL/brd-seq-fwd1 TGCCGGCCACGATGCGTCC  
SICL/brd-seq-rvr1 GGGTTCCGCGCACATTTCC  
 
ii. Cloning of the SICLOPPS library into the pET11A-BARD1 plasmid 
 The pET28-SICLOPPS plasmid served as the template for the BARD1 SICLOPPS 
library insert. Primers (figure 12) were constructed to add an AatII restriction site to the 5’ end of 
the insert fragment and an EcoRi-HF site to the 3’ end of the insert fragment.  
Figure 14. pET28-SICLOPPS/BARD1 PCR primers 
The PCR was done with Herculase as described previously. DpnI was added to the PCR reaction 
in order to digest away pET28-SICLOPPS parental vector. A PCR cleanup was then performed 
on the reaction followed by a digestion with AatII and EcoRI-HF restriction sites. The digest was 
then agarose gel extracted and a QC cleanup was performed to purify the fragment. The fragment 
was then concentrated to prepare for ligation. 
Primer Name Primer Sequence (5’ to 3’) 
SICL/brd-pcr-fwd1 AATAATAATGAATTCACGGGGCCTGCCACCATACC 
SICL/brd-pcr-rvr1 AATAATAATGACGTCATCCGGATATAGTTCCTCCTTTC
pET11a-BARD1-stfr was grown in 25 mL of 2YT/ampicillin for 12 hours at 37 °C. The 
culture was then miniprepped and digested using AatII and EcoRI-HF. The digest was then 
phenol-chloroform-isoamyl alcohol/chloroform-isoamyl alcohol extracted followed by ethanol 
precipitated followed by a second AatII/EcoRI-HF digest. The double digested DNA was then 
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agarose gel extracted followed by a QC clean up. The pET11a-BARD1-stfr vector was then 
concentrated using a spin-vac. 
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Chapter 3 – Results and Discussion 
A. Results Preface 
The overarching goal of this project was to utilize functional screens developed within 
Magliery laboratory to screen for small molecules that could rescue complex formation of 
interactions needed to stop cancer development in vivo. Both screens were developed and tested 
by other group members in Magliery laboratory. This project concerned using applying those 
screens to a SICLOPPS library and visually screen for bacteria that contained possible drug 
leads, as indicated by fluorescence expression.  
In both cases, each functional screen was constructed using two different plasmids. To 
implement SICLOPPS encoded genes to each respective system, the genes encoding the 
SICLOPPS library had to be placed within one of the plasmids. For the p53 assay, the 
pGFPuvbd1 plasmid, which contained the consensus binding domain, was chosen to be the 
plasmid for SICLOPPS addition. The reasoning for this was that this allowed for facile change of 
the p53 mutational variant being screened, which are placed within the other plasmid in the 
screen, pACBAD-p53.  
For the BRCA1/BARD1 assay, SICLOPPS was chosen to be placed in the plasmid 
containing BARD1. This was done for a reason similar to that used to justify placement in the 
p53 assay. Since BARD1 does not have many mutations reported in the literature that are 
associated with cancer, only BRCA1 mutants need to be screened for functional rescue. The 
meaning of this is that the SICLOPPS library can stay in the pET11a-BARD1 plasmid without 
needing to be recloned to test additional mutants. To test different mutants of BRCA1, only the 
BRCA1 plasmid needs to be switched out, depending on the variant needing to be studied for 
functional recovery.  
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 B. P53 Results 
i. Production of pGFPuvb1/SICLOPPS plasmid and Purity Assessment 
 
Constructing the pGFPuvbd1 plasmid is one part of a screening system that is designed to 
discover new drug scaffolds that can positively affect a protein commonly mutated in cancer, 
p53. The system has been designed to use two different plasmids (figure 15), each containing a 
different selectable resistance marker, in unison to screen large, 
genetically encoded libraries. The kanamycin resistance plasmids, which carry various p53 
variants that are under the control of an arabinose promoter, have been constructed by Brinda 
Ramasubramanian. The other part of the screening system, the pGFPuvbd1-SICLOPPS plasmid, 
are the focus of my work concerning p53.  To generate the library, which needed to be placed 
within the pGFPuvbd1 plasmid (figure 16), pET28-SICLOPPS (a gift of the Scott lab) was 
grown and miniprepped. The miniprep was then used to PCR amplify the library region within 
the plasmid (as described in the methods). 
Figure 15. A. The kanamycin plasmid, with the various p53 variants encoded where “p53 WT” ORF is. 
Figure B. The ampicillin plasmid, pGFPuvbd1-SICLOPPS with the split intein-SICLOPPS library cloned between AatII/SpeI.
[34] 
 
The PCR product was then digested using the restriction enzymes AatII and SpeI. At the same 
time, DH10B cells containing the pGFPuvbd1 plasmid were grown, miniprepped, and double 
digested using the same restriction enzymes. The fragments were ligated, which a background 
digest set up in parallel with the insert and vector ligation r ensure low background of parental 
vector. 
Figure 16. A. The vector (pGFPuvbd1) in which the SICLOPPS library was cloned into. AatII/SpeI were the sites used to clone in 
the library. EagI/BsiWI were used as a background digest. 
Figure B. The pGFPuvbd1 vector with the split intein-SICLOPPS library cloned between AatII/SpeI.
Figure 17. AatII/SpeI digest of the 
whole library. Ladder is 0.5 ng λ BsteII 
A major problem working with libraries using plasmid expression system is found in the 
vectors that the libraries are cloned in. In this case, eliminating 
pGFPuvbd1 vector from the library presented a problem. Because the 
pGFPuvbd1 vector is ampicillin resistant, just as the pGFPuvbd1-
SICLOPPS library is, it is impossible to destroy background 
contamination by selectable marker resistance alone. To combat this, 
pGFPuvbd1 was digested twice and a background digest was used. 
However, my background ligation using only pGFPuvbd1 still 
had 60 CFU compared to the greater than 1,000 CFU derived from the combined pGFPuvbd1 
and pET28-SICLOPPS insert ligation. While this is less than a 1:10 ratio, it is possible this could 
lead to problems of background noise while screening. To check and see if the background noise 
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could be better quantified, the library was miniprepped and digested with the cloning enzymes 
(figure 17). The gel shows a slight streak above and below the Vector band (3039 base pair (BP)) 
but a very distinct band that is the same size as the expected 
SICLOPPS library insert fragment (1077 BP). There is no 
noticeable band at the expected size of the pop-out band 
(334 BP, not shown).  
 The ten at random colonies picked and digested 
(figure 18) all show two uniform bands at the size of the 
expected pGFPuvbd1 vector and  
           SICLOPPS insert. However, colony 8, or lane 9, does have what seems 
to be a triplicate cut. The top band, however, is impossibly large indicating it is likely this colony 
didn’t get digested for long enough. Three of the colonies from figure 17 (lanes 2,3,9) were sent 
for sequencing and returned sequences without an mutations within the T7 promoter region to 
Figure 18. Digest(AatII/SpeI) of ten 
random colonies picked from an 
LB/ampicilin plate of the pGFPuvbd1-
SICLOPPS library. Ladder is 0.5 ng λ 
BsteII digest. 
Figure 19.Reverse (3’ to 5’) ClustalX2 of 
the three random colonies. The 15 BP 
insertion is the library. 
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the SpeI restriction site (figure 19). Only the data for reverse sequencing has been included here 
as the forward sequence did not cover the variable region.  
ii. Optimization of the p53 screen in BL21(DE3) 
Brinda Ramasubramanian constructed and optimized the maximal fluorescence levels 
seen in the negative and positive controls of the p53 binding screen for cells of the DH10B 
cloning strain. Since SICLOPPs molecules are controlled by a T7 promoter, and the DH10B 
strain does not have the cellular machinery needed to recognize a T7 promoter, the conditions of 
the screen needed to be reoptimized for the strain needed to screen the library, BL21(DE3). 
Other experiments done in the lab have shown that changing strains can alter the expression and 
fluorescence seen after plating. pGFPuvbd1 was designed with a modified lactose promoter that 
is placed upstream of a p53 consensus binding site. The screen Brinda has developed has two 
positive controls. Stabilized quadruple p53 mutant (quad) acts as the positive control, as it is 
hypothesized to bind the consensus binding domain and keep the modified lactose promoter from 
transcribing GFP, giving no fluorescence. The negative is done with wild type p53, which is 
hypothesized to be too unstable to bind the consensus binding domain, meaning the GFP 
transcription is not stopped and fluorescence is achieved. The two controls were plated side by 
side on various concentrations of IPTG, arabinose, time of incubations, and temperatures. The 
conditions chosen were 30 °C, 48 hours, 0.0075% arabinose (v/v), and 0.1 mM IPTG had the 
following qualities that made those conditions the best; The GFP level was highest in the p53 
WT streaks, the Quad streaks showed the least amount of fluorescence, and the colonies were 
large and distinct. Most 
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important, the difference between the positive and negative control is the greatest, making the 
screen more sensitive. Interestingly, the quad variant showed fluorescence at high levels (1 mM 
or above) or IPTG.  The modified lactose binding domain downstream of the consensus binding 
domain and the GFP gene should not be responsive to the amounts of IPTG added. However, it 
Figure 20. Optimization of IPTG levels in LB/0.0075% arabinose-Amp and various IPTG levels. From Top left to right 
bottom: 10mM, 1 mM, 0.5 mM, 0.1 mM, 0.5 mM, 0.1 mM. 0.1 mM was the chosen concentration. 
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is possible that increased transcription of GFP is due to an increased amount of T7 polymerase 
within the cells, since the DE3 cassette is controlled by a lactose operon.  
iii. Assessment of how SICLOPPS molecules effect the p53 screen 
A side-by-side comparison of BL21(DE3) cells containing the pGFPuvbd1-SICLOPPS  
library and DH10B cells containing the same plasmid was used to determine if expression of the 
SICLOPPS molecules could interfere with expression of GFP. Another group has demonstrated 
that SICLOPPS molecules can interfere with transcription and translation in yeast, inhibiting 
molecular based screens.91 A key difference between the DH10B cells and the BL21(DE3) cells 
is that DH10B cells do not have cellular machinery capable of transcribing gene products 
governed by a T7 promoter, as the SICLOPPS molecules are. Thus, library expression is off in 
DH10B and turned on in BL21(DE3) when lactose or a lactose analog is supplied. 
 This experiment was necessary to determine if the expression of SICLOPPS molecules could 
cause non-fluorescence when expressed.  
Figure 21. A. DH10B/ pGFPuvbd1-SICLOPPS on LB/ampiclin 
B. BL21(DE3)/pGFPuvbd1-SICLOPPS on LB/ampicilin-0.1 mM IPTG. 
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Not a single non-fluorescent colony was found during visually screening of ~3,000  
colonies of DH10B/pGFPuvbd1-SICLOPPS under UV light (302 nm λ). However, visual 
inspection of the BL21(DE3) colonies showed between a 15%-30% rate of non or low 
fluorescence, a very significant difference (figure 21). 
This indicates that many of the SICLOPPS variants, 
even with amino acids composition differences, have 
strongly negative interactions on the development of 
fluorescence at high rates. Inhibiting GFP maturation, 
whether through interference at the transcription, 
translation, or the protein folding levels makes 
screening for negative hits impossible. Figure 22 shows an enlargement of figure 21 B, 
displaying the fluorescent and non-fluorescent colonies in better detail.  
Figure 22. Enlargement of figure 21 B. Arrows 
are pointing to non-fluorescent colonies, for 
comparison. 
 In order to remedy this, more insight into if the SICLOPPS molecules are actually self 
cyclizing or if the molecules are being expressed in quantifiable amounts had to be gained. This 
was done by attempting to “reverse” the open read frame of the SICLOPPS library in the 
pGFPuvbd1 plasmid and also by attempting to purify SICLOPPS peptides. 
vi. Inversion of the SICLOPPS library with pGFPuvbd1 
 Expression the SICLOPPS libraries caused from 15% to 30% of all variants to show no 
or low fluorescence. It was unknown why this was and could be due to many reasons. It was 
hypothesized that the lack of fluorescence could be due to SICLOPPS molecule transcription out 
competing the pGFPuvbd1 gene for expression, due to the inward orientation of both reading 
frames (figure 23 A). 
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 To test this, it was decided to reverse the SICLOPPS library to see if this 
allowed a greater number of all variants to fluoresce.  
Figure 23. A. The vector (pGFPuvbd1-SICLOPPS) with the direction fo the SICLOPPS library that was first cloned. 
Figure B. The same parental vector as in figure 22 A except the SICLOPPS library has been turned reversed.
The cloning for this experiment has yet to be completed. Both the 
insert reverse SICLOPPS library and the vector have been produced and 
double digested (figure 24). Both fragments need to be concentrated, 
ligated, and then screened to see if the percentage of cells showing 
fluorescence has improved. 
Figure 24. PCR of the 
reverse SICLOPPS 
insert(~1,100 bp). Ladder 
is 0.5 ng λ BsteII digest.
v. Selection and purification of SICLOPPS peptides 
Another possibility of why SICLOPPS molecule expression resulted in failure of 
fluorescence could be that the SICLOPPS molecules are not completing the self-cyclization 
reaction. To test this, four different non-fluorescent variants were expressed as detailed in the 
methods second. These variants have yet to be sequenced so it is unknown what molecules they 
are encoded to express. Preliminary MALDI-TOF data collection has been done but more data 
needs to be collected.  
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Figure 25. Preliminary MALDI-TOF data for one of the expressed variants.  
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C. BARD1/BRCA1 Results 
i. Creation of the new parental cloning vector 
The BRCA1/BARD1 screen system system, which is based on a split-GFP complementation 
assay, relies on a two plasmid system just as the p53/consensus binding domain system does 
(figure 26). Dr. Mohosin Sarkar, a previous graduate student in Magliery Lab, created the 
plasmids for this screen. The role of this project was to clone the SICLOPPS library into the 
BARD1 plasmid. 
 
Figure 26. A. The BRCA1 half of the BRCA1/BARD1 plasmid screening system. 
B. The BARD1 half of the BRCA1/BARD1 plasmid screening system.
 The BARD1 plasmid did not contain many great restriction sites for library addition. The 
two sites chosen to place the library, AatII and EcoRI, only created an 80 base pair pop-put band. 
What this means this that no restrictions sites were placed within this pop-out, making a 
background digest impossible. The cloning was attempted once and the background was too high 
to ensure the transformation efficiency of the library could be adequately back calculated.  
 To fix this, a stuffer region from a different plasmid, pGFPuvbd1, was cloned between 
the EcoRI and AatII site. This resulted in many new choices for background digest sites. 
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Figure 27. A. The parental vector for the BARD1-SICLOPPS cloning. Shown are the desired cloning sites for the library. 
B. pET11a-BARD1-stfr with the new stuffer fragment, which is the new pop-out. SpeI/AflII are the background digest enzymes. 
Cloning a new stuffer fragment between the cloning sites eventually to be used for cloning in the 
SICLOPPS library into pET11-BARD1 was essential to ensure minimal background within the 
library. Cutting my stuffer out of the pGFPuvbd1 vector allowed for easy identification of which 
of the ligation products contained recyclized pGFPuvbd1 product. This was done using the UV 
Transilluminator, as cells containing that plasmid were fluorescent, and eliminating those cells. 
A clone was analytically digested and sequenced. It had the expected sequence and was then 
used as the cloning vector. 
ii. Cloning of the SICLOPPS library into pET11a-BARD1-STFR 
Figure 28. A. PCR of the SICLOPPS 
BARD1 insert(~1,100 bp). Ladder is 1.0 ng 
100 bp ladder. B. Gel extraction of the 
pET11a-BARD1-STFR vector. Ladder is 
0.5 ng λ BsteII digest.. 
 The SICLOPPS library, which was gifted from the Scott Lab in the pET28-SICLOPPS 
plasmid was grown and miniprepped. A PCR was 
done on the miniprep as described in the methods. 
The PCR was product was then digested using 
EcoRI and AatII restriction enzymes.  
At the same time, DH10B pET11A-BARD1-STFR 
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was grown, miniprepped, and digested twice with the same restriction sites. Both the vector and 
insert (figure 28) and ready to be concentrated, ligated, and screened. This is the next goal for 
this part of the project. 
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Chapter 4 – Conclusions and Future Directions 
 
 The usage of SICLOPPS molecules as modulators of protein function has great potential. 
Here I have described work attempting to fulfill the necessary background information for 
screening defective proteins for rescued activity upon introduction of chemical chaperones. 
Possible future directions include using FACS to sort out SICLOPPS molecules from the 
libraries that interfere with screening and then screening culled libraries in order to find drug 
leads. A similar proposition should occur with BRCA1, except that it might flow much more 
smoothly due to it being based on a positive phenotype screen.  
Drug scaffolds discovered in this way could possibly lead to drugs that target specific 
mutations in proteins, a type of medicine where one drug can modulate every human malady. 
This style of drug research has been gaining more and more credence as time has passed by, with 
drugs currently on the market that target specific maladies common to specific groups of people, 
such as the targeting of African Americans with congestive heart failure with the drug BiDil.94 
 
 
 
 
 
 
 
  
[46] 
 
 Bibliography 
1. Lane, D., Crawford, L. T antigen is bound to a host protein in SV40 transformed cells. 
Nature. 1979, 278: 170-173. 
 
2. Linzer, D., Levine, A. characterization of a 54K Dalton cellular tumor antigen present 
in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979, 17: 43-52. 
 
3. Levine, A., Oren, M. The first 30 years of p53: growing ever more complex.Nature 
Rev. 2009, 9: 749-758. 
 
4. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-
Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors 
and cell lines .Nucleic Acids Res 1994, 17: 3551-3555. 
 
5. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., 
Morel, P., Fenaux, P. p53 mutations are associated with resistance to chemotherapy and short 
survival in hematologic malignancies. Blood. 2009, 84: 3148-3157.  
 
6. Baker,S., Preisinger, A., Jessup, J., Paraskeva, C., Markowitz, S., Willson, J., 
Hamilton, S., Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions 
as late events in colorectal tumorigenesis. Cancer Res. 1990, 50: 7717-7722. 
 
 
7. Ventura, A., Kirsch, D., McLaughlin, M., Tuveson, D., Grimm, J., Lintault, L., 
Newman, J., Reczek, E., Weissleder, R., Jacks, T. Restoration of p53 function leads to tumor 
regression in vivo. Nature. 2007, 445; 661-665. 
 
8. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., Costa, J. Induction of apoptosis 
by wild-type p53 in a human colon tumor-derived cell line. PNAS. 1992, 89: 4495-4499.  
9. Malkin, D., Li, F., Strong, L., Fraumeni, J., Nelson, C., Kim, D., Kassel, J., Gryka, M., 
Bischoff, F., Tainsky, M., Friend, S. Germ line p53 mutations in a familial syndrome of breast 
cancer, sarcomas, and other neoplasms. Science. 1990, 250, 1233-1238. 
   
10. Donehower,L., Harvey, M., Slagle, B., McArthur, M., Montgomery, C., Butel, J., 
Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous 
tumours. Nature.  1992, 356: 215-221.  
 
11. Roth, J., Nguyen, D., Lawrence, D., Kemp, B., Carrasco, C., Ferson, D., Hong, W., 
Komanki, R., Lee, J., Pisters, K., Putnam, J., Schea, R., Shin, D., Walsh, G., Dolormente, M., 
Han, CI., Martin, F., Yen, N., Xu, K., Stephens, L., McDonnell, T., Mukhopadhyay, T., Cai, D. 
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. 
Med. 1996, 2: 985-991. 
 
[47] 
 
12. Wu, T., Ertl, H. Immune barriers to successful gene therapy. Trends Mol. Med. 2009, 
15: 32-39. 
 
11. Baker, S., Markowitz, S., Fearon, E., Willson, J., Vogelstein, B. Suppression of 
human colorectal carcinoma cell growth by wild-type p53. Science. 1990, 249: 912-915. 
  
13. Kuerbitz, S., Plunkett, B., Walsh, W., Kastan, M. Wild-type p53 is a cell cycle 
checkpoint determinant following irradiation. PNAS. 1992, 89: 7491-7495. 
  
14. Horn, H., Vousden, K. Coping with cellular stress: multiple ways to activate p53. 
Oncogene. 2007, 26: 1306-1316.  
 
15. Woods, D., Vousden, K. Regulation of p53 function. Exp. Cell Res. 2001, 264: 56-66. 
 
16. Honda, R., Tanaka, H., Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for 
tumor suppressor p53. FEBS Letters. 1997, 420: 25-27. 
  
17. Wu,X., Bayle, H., Olson, D., Levine, A. The p53-mdm-2 autoregulatory feedback 
loop. Genesdev. 1993, 7: 1126-1132. 
  
18. El-Deiry, W., Kern, S., Pietenpol, J., Kinzler, K., Vogelstein, B. Definition for a 
consensus binding site for p53. Nature Genetics. 1992, 1: 45-49.  
 
19. Chipuk, J., Maurer, U., Green, D., Schuler, M. Pharmacologic activation of p53 
elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003, 4: 371-381. 
 
20. El-Deiry, W. Regulation of p53 downstream genes. Sem. In Cancer Bio. 1998, 8: 
345-357.  
   
21. Weinberg, R., Veprintsev, D., Fersht, A. Cooperative binding of p53. J. Mol. Biol. 
2004, 341: 1145-1159.  
  
22. Ang, H., Joerger, A., Mayer, S., Fersht, A. Effects of common cancer mutations on 
stability and DNA binding of full-length p53 compared with isolated core domains. J. Bio. Chem. 
2006, 281: 21934-21941.  
  
23. Dawson, R., Muller, L., Dehner, A., Klein, C., Kessler, H., Buchner, J. The N-
terminal domain of p53 is natively unfolded. J. Mol. Biol. 2003, 3: 1131-1141. 
  
24. Harms, K., Chen, X. The functional domains in p53 family proteins exhibit both 
common and distinct properties. Cell Death Differ. 2006, 13: 890-897. 
  
25. Cho, Y., Gorina, S., Jeffrey, P., Pavletich, N. Crystal structure of a p53 tumor 
suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994, 265: 346-355. 
  
[48] 
 
26. Jeffrey, P., Gorina, S., Pavletich, N. Crystal structure of the tetramerization domain 
of the p53 tumor suppressor at 1.7 angstroms.  
  
27. Bell, S., Klein, C., Muller, L., Hansen, S., Bucnher, J. p53 contains large 
unstructured regions in its native state. J. Mol. Biol. 2002, 322: 9170927. 
  
28. Viadiu, H. Molecular architecture of tumor suppressor p53. Curr. Topic Med. Chem. 
2008, 8: 1327-1334. 
 
29. Olivier, M., Eeles, R., Hollstein, M., Khan, M., Harris, C., Hainaut, P. The IARC 
TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 
19: 607-614. 
  
30. Pavletich, N., Chambers, K., Pabo, C. The DNA-binding domain of p53 contains four 
conserved regions and the major mutation hot spots. Genes Dev. 1993, 7: 2556-2564. 
  
31. Hainaut,P., Milner, J. A structural role for metal ions in the “wild-type” 
conformation of the tumor suppressor protein p53. Can. Res. 1993, 53: 1739-1742. 
  
32. Kwon, E., Kim, D., Suh, S., Kim, K. Crystal structure of the mouse p53 core domain 
in zinc-free state. Proteins. 2007, 10: 280-283.  
  
 
33. Joerger, A., Fersht, A. Structural biology of the tumor suppressor p53 and cancer-
associated mutants. Adv. Can. Res. 2007. 
  
34. Bullock, A., Henckel, J., DeDecker, B., Johnson, C., Nikolova, P., Proctor, M., Lane, 
D., Fersht, A. Thermodynamic stability of wild-type and mutant p53 core domain. PNAS. 1997, 
94: 14338-14342. 
  
35. Bullock, A., Henckel, J., Fersht, A. Quantitative analysis of residual folding and DNA 
binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. 
Oncogene. 2000, 19: 1245-1256. 
  
36. Nikolova, P., Henckel, J., Lane, D., Fersht, A. Semirational design of active tumor 
suppressor p53 DNA binding domain with enhanced stability. PNAS. 95: 14675-14680. 
  
37. Joerger, A., Allen, M., Fersht, A. Crystal structure of a superstable mutant of human 
p53 core domain. J. Bio. Chem. 2004, 279: 1291-1296. 
  
 
38. Magliery, T. Unpublished data. 
 
39. Hall, J., Lee, M., Newman, B., Morrow, J., Anderson, L., Huey, B., King, M. Linkage 
of early-onset familial breast cancer to chromosome 17q21. Science. 1990, 250: 1684-1689. 
  
[49] 
 
40. Ford, D., Easton, D. Risk of cancer in BRCA1-mutation carriers. Lancet. 1994, 343: 
692-695. 
  
41. Scata, K., El-Deiry, W. p53, BRCA1, and breast cancer chemoresistance. Breast 
Cancer Chemosensitivity. 2007. 
 
42. Foray, N., Randrianarison, V., Marot, D., Perricaudet, M., Lenoir, G., Feunteun, J. 
Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene. 
1999, 18: 7334-7342. 
  
43. Weaver, Z., Montagna, C., Xu, X., Howard, T., Gadina, M., Brodie, S., Deng, CX., 
Ried, T. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic 
instability and centrosome amplification yet display a recurring distribution of genomic 
imbalances that is similar to human breast cancer. Oncogene. 2002, 21: 5097-5107. 
 
44. Xu, X., Qiao, W., Linke, S., Cao, L., Li, WM., Furth, P., Harris, C., Deng, CX. 
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and 
tumorigenesis. Nature Genetics. 2001, 28: 266-271. 
 
45. Hakem, R., Pompa, J., Elia, A., Potter, J., Mak, T. Partial rescue if Brca1 early 
embryonic lethality by p53 or p21 null mutation. Nature Genetics. 1997, 16: 298-302. 
 
46. McCarthy, E., Celebi, J., Baer, R., Ludwig, T. Loss of Bard1, the heterodimeric 
partner of the BRCA1 tumor suppressor, results in early embryonic lethality and chromosomal 
instability. 2003, 23: 5056-5063. 
 
47. Shakya, R., Szabolcs, M., McCarthy, E., Ospina, E., Basso, K., Nandula, S., Murty, 
V., Baer, R., Ludwig, T. The basal-like mammary carcinomas induced by Brca1 or Bard1 
inactiviation implicate the BRCA1/BARD1 heterodimer in tumor suppression. PNAS. 2008, 105: 
7040-7045.  
  
48. Moynahan, M., Cui, T., Jasin, M. Homology-directed DNA repair, Mitomycin-C 
resistance, and Chromosome stability is restored with correction of a BRCA1 mutation. Cancer 
Research. 2001, 61: 4842-4850. 
  
49. Zhong, Q., Chen, CF., Li, S., Chen, Y., Wang, CC., Xiao, J., Chen, PL., Sharp, Z., 
Lee, WH. Association of BRCA1 with hRAD50-hMre11-p95 complex and the DNA damage 
response. Science. 1999, 285: 747-750. 
  
50. Mullan, PB., Quinn, JE., Harkin, DP. The Role of BRCA1 in transcriptional e 
regulation and cell cycle control. Oncogene. 2006, 25: 5854-5863. 
 
51. Lou, Z., Minter-Dykhouse, K., Chen, J. BRCA1 participates in DNA decatenation. 
Naure Struc. Mol. Bio. 2005, 12: 589-593. 
  
[50] 
 
52. Wu, W., Koike, A., Takeshita, T., Ohta, T. The Ubiquitin E3 Ligase activity of 
BRCA1 and its biological effects. Cell Div. 2008, 3:1.  
  
53. Wu, W., Nishikawa, H., Hayami, R., Sato, K., Honda, A., Aratani, S., Nakajima, T., 
Fukuda, M., Ohta, T. BRCA1 ubiquitinates RPB8 in response to DNA damage. Cancer Res. 
2007, 67:951-958. 
  
54. Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, MS., Timmers, C., Hejna, J., 
Grompe, M., D’Andrea, AD. Interaction of the Fanconi anemia proteins and BRCA1 in a 
common pathway. Mol. Cel. 2001, 7: 249-262. 
  
55. Kleiman, FE., Wu-Baer, F., Fonseca, D., Kaneko, S., Baer, R., Manley, JL. 
BRCA1/BARD1 inhibition of mRNA 3’ processing involves targeted degradation of RNA 
polymerase II. Genes Dev. 2005, 19: 1227-1237. 
  
56. Xia, Y., Pao, G., Chen, HW., Verma, I., Hunter, T. Enhancement of BRCA1 E3 
ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Bio. Chem. 2003, 
7: 5255-5263. 
 
57. Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, 
H., Ohta, T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast 
cancer-derived mutation. J. Biol. Chem. 2001, 18: 14537-14540. 
  
58. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P., Harshman, K., Tavtigian, S., 
Liu, Q., Cochran, C., Bennett, L., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., 
McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., 
Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayanath, P., Ward, J., 
Tonin, P., Narod, S., Bristow, P., Norris, F., Helvering, L., Morrison, P., Rosteck, P., Lai, M., 
Barrett, J., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., 
Skolnick, M. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene 
BRCA1. Science. 266: 66-71. 
  
59. Williams, R., Green, R., Glover, J. Crystal structure of the BRCT repeat regions from 
the breast cancer-associated protein BRCA1. Nat. Struc. Bio. 2001, 10: 838-842. 
  
60. Meza, J., Brzovic, P., King, MC., Klevit, R. Mapping the functional domains of 
BRCA1. J. Biol. Chem. 1999, 9: 5659-5665. 
  
61. Saurin, A., Borden, K., Boddy, M., Freemont, P. Does this have a familiar RING? 
TIBS. 1996, 21: 208-214. 
  
62. Schwabe, J., Klug, A. Zinc mining for protein domains. Struct. Bio. 1994, 6: 345-349 
  
63. Brzovic, P., Rajagopal, P., Hoyt, D., King, MC., Klevit, R. Structure of a BRCA1-
BARD1 heterodimeric RING-RING complex. Nat. Struct. Bio. 2001, 8: 833-837. 
  
[51] 
 
64. Wu, L., Wang, Z., Tsan, J., Spillman, M., Phung, A., Xu, X., Yang, MC., Hwang, 
LY., Bowcock, A., Baer, R. Identification of a RING protein that can interact with the BRCA1 
gene product. Nat. Gen. 1996, 14: 430-440. 
  
65. Brzovic, P., Meza, J., King, MC., Klevit, R. The Cancer-predisposing mutation C61G 
disrupts Homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 
1998, 273: 7795-7799. 
  
66. Brzovic, P., Meza, J., King, MC., Klevit, R. BRCA1 RING domain cancer-
predisposing mutations. J. Biol. Chem. 2001, 276: 41399-41406. 
  
67. Sarkar, M., Magliery, T. Re-engineering a split-GFP reassembly screen to examine 
interactions between BARD1 and BRCA1 mutants observed in cancer patients. Mol. BioSystems. 
2008, 4: 599-605. 
 
68. Brzovic, P., Keeffe, J., Nishikawa, H., Miyamoto, K., Fox, D., Fukuda, M., Ohta, T., 
Klevit, R. Binding and recognition in the assembly of an active BRCA1/BARD1 ubuitin-ligase 
complex. PNAS. 2003, 100: 5646-5651. 
  
69.  Morris, J., Keep, N., Solomon, R. Identification of Residues Required for the 
Interaction of BARD1 with BRCA1. J. Biol. Chem. 2002, 277: 9382-9386. 
  
70. Thai, T., Du, F., Tsan, J., Jin, Y., Phung, A., Spillman, M., Massa, H., Muller, C., 
Ashfaq, R., Mathis, J., Miller, D., Trask, B., Baer, R., Bowcock, A. Mutations in the BRCA1-
associated domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum. Mol. 
Gen. 1998, 7: 195-202. 
  
71. Zhu, H., Bilgin, M., Snyder, M. Proteomics. Annu. Rev. Biochem. 2003, 72: 783-
812. 
 
72. Piehler, J. New methodologies for measuring protein interactions in vivo and in vitro. 
Curr. Opin. Struct. Bio. 2005, 15: 4-14.  
 
 
73. Ghosh, I., Hamilton, A., Regan, L. Antiparallel leucine zipper-directed protein 
reassembly: application to the green fluorescent protein. J. Am. Chem. Soc. 2000, 122: 5658-
5659. 
 
74. Magliery, T., Wilson, C., Pan, W., Mishler, D., Ghosh, I., Hamilton, A., Regan, L. 
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly: 
scope and mechanism. J. Am. Chem. Soc. 2005, 127: 146-157. 
 
75. Clackson, T., Wells, J. A hot spot of Binding Energy in a Hormone-Receptor 
Interface. Science. 1995, 267: 383-386. 
  
[52] 
 
76. Vassilev, L., Vu, B., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., 
Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., Liu, E. In Vivo activation of the p53 pathway 
by Small-Molecule antagonists of MDM2. Science. 2004, 303: 844-848. 
  
77. Oltersdorf, T., Elmore, S., Shoemaker, A., Armstrong, R., Augeri, D., Belli, B., 
Bruncko, M., Deckwerth, T., Dinges, J., Hajduk, P., Joseph, M., Kitada, S., Korsmeyer, S., 
Kunzer, A., Letai, A., Li, C., Mitten, M., Nettesheim, D., Ng, SC., Nimmer, P., O’Conner, J., 
Oleksijew, A., Petros, A., Reed, J., Shen, W., Tahir, S., Thompson, C., Tomaselli, K., Wang, B., 
Wendt, M., Zhang, H., Fesik, S., Rosenberg, S. An inhibitor of Bcl-2 family proteins induces 
regression of solid tumors. Nature. 2005, 435: 677-681. 
 
78. Friedler, A., Veprintsev, D., Hansson, L., Fersht, A. Kinetic instability of p53 Core 
domain mutants. J. Biol. Chem. 2003, 278: 24108-24112. 
 
79. Friedler, A., Hansson, L., Veprintsev, D., Freund, S., Rippin, T., Nikolova, P., 
Proctor, M., Rudiger, S., Fersht, A. A peptide that binds and stabilizes p53 core domain: 
Chaperone stratergy for rescues of oncogenic mutants. PNAS. 2002, 99: 937-942.  
 
80. Lambert, J., Gorzov, P., Veprintsev, D., Soderqvist, M., Segerback, D., Bergman, J., 
Fersht, A., Hainaut, P., Wiman, K., Bykov, V. PRIMA-1 reactivates mutant p53 by covalent 
binding to the core domain.  Cancer C ell. 2009, 15: 376-388. 
 
81. Boeckler, F., Joerger, A., Jaggi, G., Rutherford, T., Veprintsev, D., Fersht, A. 
Targeted rescue of a destabilized mutant of p53 by an in silico drug. PNAS. 2008, 105: 10360-
10365. 
 
82. Basse, Nicolas, Kaar, J., Settanni, G., Joerger, A., Rutherford, T., Fersht, A. Toward 
The Rational Design of p53-Stabilizing drugs: Probing the surface of the oncogenic Y220C 
mutant. Chem. Bio. 2010, 17: 46-56. 
 
83. Troitskaya, L., Kodadek, T. Peptides as modulators of enzymes and regulatory 
proteins. Methods. 2004, 32: 406-415. 
 
84. Werle, M., Bernkop-Schnurch, A. Strategies to improve plasma half life time of 
peptide and protein drugs. Amino Acids. 2006, 30: 351-367. 
 
85. Rizo, J., Gierasch, L. Constrained peptides: models of bioactive peptides and protein 
substructures. Annu. Rev. Biochem. 1992, 61: 387-418.  
 
86. Zang, X., Yu, Z., Chu, YH. Tight-binding strepavidin ligands from a cyclic peptide 
library. Bioorg. Med. Chem. Letters. 1998, 8: 2327-2332. 
 
87. Scott, C., Abel-Santos,  E., Wall, M., Wahnon, D., Benkovic, S. Production of cyclic 
peptides and proteins in vivo. PNAS. 1999, 96: 13638-13643. 
 
[53] 
 
[54] 
 
88. Wu, H., Hu, Z., Liu, XQ. Protein trans-splicing by a split intein encoded in a split 
DnaE gene of synechocystis sp. PCC6803. PNAS. 1998, 95: 9226-9231.  
 
 
89. Evans, T., Xu, MQ. Mechanistic and kinetic considerations of protein splicing. 
Chem. Rev. 2002, 102: 4869-4883.  
 
90.  Scott, C., Abel-Santos, E., Jones, A., Benkovic, S. Structural requirements for the 
biosynthesis of backbone cyclic peptide libraries. Chem. Bio. 2001, 8: 801-815. 
 
91. Kritzer, J., Hamamichi, S., McCaffery, J., Santagata, S., Naumann, T., Caldwell, K., 
Caldwell, G., Lindquist, S. Rapid selection of cyclic peptides that reduce α-synnuclein toxicity in 
yeast and animal models. Nat. Chem. Bio. 2009, 5: 655-663.  
 
92. Naumann, T., Tavassoli, A., Benkovic, S. Genetic Selection of cyclic peptide dam 
methyltransferase inhibitors. Chem. Bio. Chem. 2008, 9: 194-197.  
 
93. Horswill, A., Savinov, S., Benkovic, S. A systematic method for identifying small-
molecule modulators of protein-protein interactions. PNAS. 2004, 101: 15591-15596.  
 
 
94.  Wadman, M. Drug targeting: is race enough? Nature. 2005. 435: 1008-1009. 
 
